Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation
Journal of Affective Disorders · 2026
DOI: 10.1016/j.jad.2025.121132 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Jen-Ping Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Transcranial Magnetic Stimulation, Ketamine, Antidepressive Agents. Die Arbeit nennt 40 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) and esketamine are FDA-approved treatments for treatment-resistant depression (TRD), yet head-to-head comparative effectiveness data remain limited. Our study compared the effectiveness and safety profiles of rTMS versus esketamine in adults with TRD. METHODS: This cohort study used target trial emulation with 1:1 propensity score matching on 50 covariates using de-identified electronic health records from TriNetX US Collaborative Network. Adults aged 18-65 years with TRD who initiated rTMS or esketamine between March 2019 and September 2025 were included. After matching, 1690 patients remained in each cohort. RESULTS: Overall, rTMS was associated with a higher, but not statistically significant, risk of suicide-related outcomes compared to esketamine (reported as hazard ratio with 95 % confidence interval: 1.199, 0.943-1.526), while the 30-90-day interval was statistically significant (1.496, 1.031-2.170). For safety outcomes, rTMS was associated with a lower risk of hospitalization than esketamine (0.746, 0.646-0.861), lower risks of arrhythmia (0.677, 0.485-0.943) and any injury (0.745, 0.627-0.885), which attenuated over longer follow-up. The risk differences of hypertension and seizure were not statistically significant. In subgroup analyses, esketamine's protective association against suicide was more evident among patients aged 45-65 years, whereas the safety advantages of rTMS were particularly evident in males. CONCLUSIONS: rTMS was associated with fewer medical complications, suggesting a more favorable overall medical safety profile over the first year. Suicide-related outcomes were broadly comparable overall, although esketamine showed an advantage during the 30-90-day interval and among patients aged 45-65 years, which should be interpreted cautiously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
- Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiun…
- Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan; Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan; Prospect Clinic for Otorhinolaryn…
- Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Psychiatry, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Psychiatry, E-DA Dachang Hospital, I-Shou University, Kaohsiung, Taiwan; Department of Psychiatry, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan; Graduate Institute of Clinical Medicine, College of M…
Zitieren
APA
Chen, J. P., Hsu, C. W., Chen, Y. T., Fang, Y. Y., Tseng, P. T., Chen, M. H., Kao, Y. C., Hsu, T. W., & Liang, C. S. (2026). Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.121132
Vancouver
Chen JP, Hsu CW, Chen YT, Fang YY, Tseng PT, Chen MH, et al. Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2025.121132
BibTeX
@article{Chen2026,
author = {Chen, Jen-Ping and Hsu, Chih-Wei and Chen, Yi-Ting and Fang, Yi-Ya and Tseng, Ping-Tao and Chen, Mu-Hong and Kao, Yu-Chen and Hsu, Tien-Wei and Liang, Chih-Sung},
title = {Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation},
journal = {Journal of Affective Disorders},
year = {2026},
doi = {10.1016/j.jad.2025.121132}
}
EUVIMED